IDEAS home Printed from https://ideas.repec.org/e/pgu92.html
   My authors  Follow this author

Ilan Guedj

Personal Details

First Name:Ilan
Middle Name:
Last Name:Guedj
Suffix:
RePEc Short-ID:pgu92
[This author has chosen not to make the email address public]
https://www.bateswhite.com/people-Ilan-Guedj.html
2001 K Street NW North Building, Suite 500 Washington, DC 20006
202-652-4388

Affiliation

Bates White Economic Consulting (Bates White Economic Consulting)

https://www.bateswhite.com/
Washington, DC

Research output

as
Jump to: Working papers

Working papers

  1. Ilan Guedj & David Scharfstein, 2004. "Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms," NBER Working Papers 10933, National Bureau of Economic Research, Inc.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Ilan Guedj & David Scharfstein, 2004. "Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms," NBER Working Papers 10933, National Bureau of Economic Research, Inc.

    Cited by:

    1. Laura McNamee & Fred Ledley, 2013. "Translational Science by Public Biotechnology Companies in the IPO“Class of 2000”: The Impact of Technological Maturity," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-7, December.
    2. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
    3. Seru, Amit, 2014. "Firm boundaries matter: Evidence from conglomerates and R&D activity," Journal of Financial Economics, Elsevier, vol. 111(2), pages 381-405.
    4. M. Lourdes Sosa, 2009. "Application-Specific R& D Capabilities and the Advantage of Incumbents: Evidence from the Anticancer Drug Market," Management Science, INFORMS, vol. 55(8), pages 1409-1422, August.
    5. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
    6. Martin Backfisch, 2018. "The Development of Firm Size and Innovativeness in the Pharmaceutical industry between 1989 and 2010," MAGKS Papers on Economics 201813, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
    7. Marinelli, Federico, 2008. "Persistence of outstanding performance and shareholder value among diversified firms: The impact of past performance, efficient internal capital market, and relatedness of business segments," IESE Research Papers D/758, IESE Business School.
    8. Ashish Arora & Andrea Fosfuri & Thomas Roende, 2018. "Waiting for the Payday? The Market for Startups and the Timing of Entrepreneurial Exit," NBER Working Papers 24350, National Bureau of Economic Research, Inc.
    9. Lorenzo Casavecchia & Ja Young Suh, 2017. "Managerial incentives for risk-taking and internal capital allocation," Australian Journal of Management, Australian School of Business, vol. 42(3), pages 428-461, August.
    10. Kyle, Margaret & Allain, Marie-Laure, 2011. "Inefficiencies in technology transfer: theory and empirics," CEPR Discussion Papers 8206, C.E.P.R. Discussion Papers.
    11. Hvide, Hans K. & Kristiansen, Eirik Gaard, 2012. "Management of Knowledge Workers," IZA Discussion Papers 6609, Institute of Labor Economics (IZA).
    12. Finn Valentin & Henrich Dahlgren & Rasmus Lund Jensen, 2006. "Research Strategies in Science-based Start-ups - Effects on performance in Danish and Swedish biotechnology," DRUID Working Papers 06-11, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
    13. Siraj, Ibrahim & Hassan, M. Kabir & Maroney, Neal, 2020. "Product demand sensitivity and the corporate diversification discount," Journal of Financial Stability, Elsevier, vol. 48(C).
    14. Sharon Belenzon & Tomer Berkovitz, 2007. "Innovation in Business Groups," CEP Discussion Papers dp0833, Centre for Economic Performance, LSE.
    15. Kim, Tae-Nyun & Palia, Darius, 2014. "Private equity alliances in mergers," Journal of Empirical Finance, Elsevier, vol. 27(C), pages 10-20.
    16. M. Lourdes Sosa, 2014. "Corporate Structure, Indirect Bankruptcy Costs, and the Advantage of De Novo Firms: The Case of Gene Therapy Research," Organization Science, INFORMS, vol. 25(3), pages 850-867, June.
    17. Hans K. Hvide, 2009. "The Quality of Entrepreneurs," Economic Journal, Royal Economic Society, vol. 119(539), pages 1010-1035, July.
    18. Giroud, Xavier & Dai, Min & Jiang, Wei & Wang, Neng, 2020. "A q Theory of Internal Capital Markets," CEPR Discussion Papers 15341, C.E.P.R. Discussion Papers.
    19. Oliver Boguth & Ran Duchin & Mikhail Simutin, 2022. "Dissecting Conglomerate Valuations," Journal of Finance, American Finance Association, vol. 77(2), pages 1097-1131, April.
    20. Bai, Min & Fu, Yumei & Sun, Mingwei, 2023. "Corporate diversification and labor investment efficiency: Evidence from China," Economic Modelling, Elsevier, vol. 127(C).
    21. Vitkova, Valeriya & Tian, Siyang & Sudarsanam, Sudi, 2023. "Allocative efficiency of internal capital markets: Evidence from equity carve-outs by diversified firms," International Review of Financial Analysis, Elsevier, vol. 86(C).
    22. Stéphane Koffel & Jonathan Labbé, 2020. "Analyse comparée des financements par capital-investissement ou Business Angel : Un effet sur l'innovation ?," Post-Print hal-03161525, HAL.
    23. Joseph Golec & Shantaram Hegde & John A. Vernon, 2005. "Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending," NBER Working Papers 11229, National Bureau of Economic Research, Inc.
    24. Hoang, Daniel & Gatzer, Sebastian & Ruckes, Martin E., 2018. "The economics of capital allocation in firms: Evidence from internal capital markets," Working Paper Series in Economics 115, Karlsruhe Institute of Technology (KIT), Department of Economics and Management.
    25. Sharon Belenzon & Tomer Berkovitz & Patrick Bolton, 2009. "Intracompany Governance and Innovation," NBER Working Papers 15304, National Bureau of Economic Research, Inc.
    26. Belenzon, Sharon & Berkovitz, Tomer, 2007. "Innovation in business groups," LSE Research Online Documents on Economics 19661, London School of Economics and Political Science, LSE Library.
    27. Duncan Simester & Juanjuan Zhang, 2010. "Why Are Bad Products So Hard to Kill?," Management Science, INFORMS, vol. 56(7), pages 1161-1179, July.
    28. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680, December.
    29. Gatzer, Sebastian & Hoang, Daniel & Ruckes, Martin, 2014. "Internal capital markets and diversified firms: Theory and practice," Working Paper Series in Economics 64, Karlsruhe Institute of Technology (KIT), Department of Economics and Management.
    30. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
    31. Benz, Andreas & Demerjian, Peter R. & Hoang, Daniel & Ruckes, Martin E., 2024. "Picking winners: Managerial ability and capital allocation," Working Paper Series in Economics 163, Karlsruhe Institute of Technology (KIT), Department of Economics and Management.
    32. Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2016. "Competition and the Efficiency of Markets for Technology," Management Science, INFORMS, vol. 62(4), pages 1000-1019, April.
    33. Catherine Bobtcheff & Raphaël Levy, 2017. "More Haste, Less Speed? Signaling through Investment Timing," American Economic Journal: Microeconomics, American Economic Association, vol. 9(3), pages 148-186, August.
    34. Gatzer, Sebastian & Hoang, Daniel & Ruckes, Martin, 2015. "Internal Capital Markets and Diversified Firms: Theory and Practice," EconStor Preprints 169432, ZBW - Leibniz Information Centre for Economics.
    35. Cohen, Susan & Fehder, Daniel C. & Hochberg, Yael V. & Murray, Fiona, 2019. "The design of startup accelerators," Research Policy, Elsevier, vol. 48(7), pages 1781-1797.
    36. Arora, Ashish & Gambardella, Alfonso & Magazzini, Laura & Pammolli, Fabio, 2007. "A Breath of Fresh Air? Firm types, scale, scope and selection effects in drug development," MPRA Paper 16042, University Library of Munich, Germany.
    37. Stéphane Koffel & Jonathan Labbé, 2020. "Comparative analysis of financing by Private Equity or Business Angels: An effect on innovation? [Analyse comparée des financements par Capital-Investissement ou Business Angels : Un effet sur l’in," Working Papers hal-03000133, HAL.
    38. Malcolm Baker & Richard S. Ruback & Jeffrey Wurgler, 2004. "Behavioral Corporate Finance: A Survey," NBER Working Papers 10863, National Bureau of Economic Research, Inc.
    39. Yaroslav Kryukov, "undated". "Dynamic R&D and the Effectiveness of Policy Intervention in the Pharmaceutical Industry," GSIA Working Papers 2015-E33, Carnegie Mellon University, Tepper School of Business.
    40. Beshears, John, 2013. "The performance of corporate alliances: Evidence from oil and gas drilling in the Gulf of Mexico," Journal of Financial Economics, Elsevier, vol. 110(2), pages 324-346.
    41. Mehmet Nasih Tağ, 2022. "The Dark Side of Firm Diversity: An Empirical Examination of the Impact of Firm Diversity on Resource Allocation Efficiency in Multidivisional Firms," Istanbul Business Research, Istanbul University Business School, vol. 51(2), pages 643-668, November.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 1 paper announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-COM: Industrial Competition (1) 2004-12-02
  2. NEP-HEA: Health Economics (1) 2004-12-02

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Ilan Guedj should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.